Your Good Partner in Biology Research

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human apolipoprotein A1 (Apo-A1) ELISA Kit

Human apolipoprotein A1 (Apo-A1) ELISA Kit

  • 中文名稱：
    人載脂蛋白A1(Apo-A1)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E08103h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
        APOA1 (Apolipoprotein A1)是一種由肝臟細(xì)胞合成的高密度脂蛋白（HDL）的主要結(jié)構(gòu)蛋白質(zhì)，參與膽固醇的逆向轉(zhuǎn)運(yùn)和脂質(zhì)代謝。它與其他蛋白質(zhì)一起形成HDL顆粒，通過與組織中游離的膽固醇結(jié)合并將其運(yùn)輸?shù)礁闻K進(jìn)行代謝，從而降低血液中膽固醇的水平。
        華美生物所提供的Human apolipoprotein A1 (Apo-A1) ELISA Kit屬于ELISA檢測(cè)試劑盒，采用雙抗夾心法定量檢測(cè)人血清、血漿、細(xì)胞培養(yǎng)上清、唾液、尿液樣本中的APOA1，其靈敏度為0.7 ng/mL，檢測(cè)范圍為1.4 ng/mL-1000 ng/mL。
     
  • 別名：
    Apo-AI ELISA Kit; ApoA I ELISA Kit; ApoA-I ELISA Kit; APOA1 ELISA Kit; APOA1_HUMAN ELISA Kit; Apolipoprotein A-I(1-242) ELISA Kit; Apolipoprotein A1 ELISA Kit; Apolipoprotein AI ELISA Kit; Apolipoprotein of high density lipoprotein ELISA Kit; ApolipoproteinAI ELISA Kit; Brp14 ELISA Kit; high density lipoprotein uptake ELISA Kit; Ltw1 ELISA Kit; Lvtw1 ELISA Kit; MGC117399 ELISA Kit; Sep1 ELISA Kit; Sep2 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, cell culture supernates, saliva, urine
  • 檢測(cè)范圍：
    1.4 ng/mL-1000 ng/mL
  • 靈敏度：
    0.7 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Cardiovascular
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human Apo-A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:2000 Average % 88  
    Range % 84-92  
    1:4000 Average % 96  
    Range % 92-102  
    1:8000 Average % 95  
    Range % 89-100  
    1:16000 Average % 92  
    Range % 89-96  
  • 回收率：
    The recovery of human Apo-A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 94 89-98  
    EDTA plasma (n=4) 96 91-101  
                 
                 
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    1000 1.879 1.903 1.891 1.728  
    500 1.592 1.612 1.602 1.439  
    250 1.304 1.311 1.308 1.145  
    125 0.955 0.968 0.962 0.799  
    62.5 0.743 0.757 0.750 0.587  
    31.2 0.562 0.572 0.567 0.404  
    15.6 0.374 0.376 0.375 0.212  
    0 0.161 0.165 0.163 　  
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

引用文獻(xiàn)

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
        最新研究表明，APOA1在心血管疾病、代謝性疾病、神經(jīng)系統(tǒng)疾病等多個(gè)方面都具有重要作用。其中，研究人員發(fā)現(xiàn)APOA1能夠促進(jìn)膽固醇從動(dòng)脈壁中流失，防止動(dòng)脈粥樣硬化的發(fā)生；同時(shí)，APOA1也能夠抑制腫瘤的生長(zhǎng)和轉(zhuǎn)移，具有一定的抗腫瘤作用。此外，一些研究還發(fā)現(xiàn)，APOA1在神經(jīng)系統(tǒng)疾病中也起到了重要作用，能夠保護(hù)神經(jīng)細(xì)胞、促進(jìn)神經(jīng)修復(fù)。
  • 功能：
    Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
  • 基因功能參考文獻(xiàn)：
    1. Plasma apoA-I proteolysis is augmented in aortic valve stenosis and cathepsin S exerts the most deleterious effects on apoA-I integrity in humans. PMID: 29915952
    2. This study explores how the high-density lipoproteins lipid composition influences amyloid deposition by apoA-I and related proteins. PMID: 27768903
    3. Site-specific, covalent modifications of apoA-I (lysines or arginines) led to altered protein structure, reduced lipid binding capability and a reduced ability to catalyze cholesterol efflux from macrophages, partly in a modification-specific manner. PMID: 29802959
    4. assessing the quality of ApoA1 and, in turn, that of HDL in circulating blood can serve as an early diagnostic tool for cardiovascular diseases (CVDs). In this study, we developed monoclonal antibodies (mAbs) specific to modified ApoA1 with its tyrosine residue at the 166th position nitrated to 3-nitrotyrosine PMID: 30132720
    5. Vitreous levels of APOA1 and RBP4 in human rhegmatogenous retinal detachment associated with choroidal detachment reflects the severity of disease. PMID: 29618920
    6. The objective of this study was to evaluate whether apolipoprotein gene polymorphisms confer susceptibility to osteonecrosis of the femoral head. PMID: 30119683
    7. Case Report: recurrence of non-familial hereditary apolipoprotein A-I amyloidosis in Japanese transplant recipient with two novel APOA1 mutations. PMID: 29968409
    8. TNFalpha differently regulated the levels of PPARalpha, LXRalpha, and LXRbeta binding to the apoA-I gene promoter in THP-1 cells. Obtained results suggest a novel tissue-specific mechanism of the TNFalpha-mediated regulation of apoA-I gene in monocytes and macrophages and show that endogenous ApoA-I might be positively regulated in macrophage during inflammation. PMID: 29442267
    9. An increased apo B/apo A1 ratio was independently associated with all-cause mortality and cardiovascular events in peritoneal dialysis patients. PMID: 29776362
    10. he present study reveals that there may be a racial/ethnic- and/or gender-specific association between the APOA1 rs964184 SNP and serum lipid parameters in our study populations PMID: 29747660
    11. In this study the APOA1 (rs670) gene showed important effects on body weight, adiposity, LDL-cholesterol levels and insulin resistance after 12weeks of the dietary intervention PMID: 29859275
    12. Residues 26-43 of one APOA1 in the smaller particle form a hinge on the disc edge, which displaces the C-terminal domain of the other APOA1 to the phospholipid surface PMID: 29712830
    13. H1 receptor signaling is a novel pathway of apo A1 gene expression PMID: 29378195
    14. genetic polymorphisms of ApoA1 rs5070 A/G may play a role in the susceptibility to large artery atherosclerosis among male diabetic patients. PMID: 28238629
    15. Single Nucleotide Polymorphism in APOA1 gene is associated with dyslipidemia. PMID: 29758034
    16. rs670, rs2854116, and rs662799 single nucleotide polymorphisms of the APOA1-C3-A5 cluster are associated with ischemic stroke in the northern Chinese Han population. PMID: 28635360
    17. Higher levels of TG, LPO (P<0.0001), nonHDL/HDL and ApoB/ApoA1 (P<0.001, 0.05, respectively), and lower levels of HDL-c, ApoA1, and PON1 (P<0.0001) were observed in T2DM subjects than in controls. PMID: 29626583
    18. Data suggest that N(epsilon)-(carboxyethyl)lysine (CEL) modification of ApoA1 is up-regulated in serum from patients with Alzheimer's disease (AD); CEL-ApoA1 is a kind of advanced glycation end product; this leads to up-regulation of anti-CEL-ApoA1 IgM in early disease. Both CEL and anti-CEL IgM may serve as AD biomarkers. PMID: 29680706
    19. The osteonecrosis of the femoral head patients had higher A/A genotype proportions on the apolipoprotein A1 gene 75bp, compared to the control group, while the G/A genotype frequency was lower in the affected patients. This suggests that the G/A mutation on Apo A1 promoter might be one of the predisposing factors for osteonecrosis of the femoral head. PMID: 28770971
    20. Independent evidence indicated LpAI:A-II has a diameter 20% smaller than LpAI, consistent with a model having two apoA-I and one apoA-II PMID: 27526664
    21. ApoA1 combined with 9alpha,11ss-PGF2 represents a useful composite biomarker of anaphylaxis, achieving superior diagnostic power over either factor alone. PMID: 28378321
    22. Low-dose lipid-free apoA-I treatment in atherosclerotic mice preserves and restores collecting lymphatic vessels function by direct and indirect mechanisms. PMID: 28939717
    23. APOA1 gene may be associated with low HDL-cholesterol disease in the pastoral area of northwest China. PMID: 28969676
    24. Our results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. PMID: 29031392
    25. A multidisciplinary approach, including circular dichroism, dynamic light scattering, spectrofluorometric and atomic force microscopy analyses, monitored the effect of target cells on the conformation and fibrillogenic pathway of the two AApoAI amyloidogenic variants AApoAI(L75P) and AApoAI(L174S). Specific cell milieus selectively affect conformation, aggregation propensity and fibrillogenesis of these variants. PMID: 29174954
    26. we demonstrated a 21.6% decrease in serum ApoA-I in FA patients compared with non-affected controls PMID: 29447225
    27. Smaller apolipoprotein(a) isoform size and increased lipoprotein(a) concentration are independent and causal risk factors for coronary heart disease. PMID: 28408323
    28. In conclusion, decreasing levels of apolipoproteins B and A1 were associated with increased risk of venous thrombosis. PMID: 28540474
    29. Serum ApoA-I level was negatively correlated with the formation of vocal fold polyps, suggesting ApoA-I may reduce the risk of vocal fold polyps. PMID: 27816355
    30. data indicate that low apoA1 levels are an independent predictor of the poor clinical outcomes in invasive ductal carcinoma patients. PMID: 28595037
    31. Data suggest that Apolipoprotein A1 (ApoA-1) might be a promising therapeutic target to reduce recurrence and metastasis for hepatocellular carcinoma (HCC) patients after resection. PMID: 27683106
    32. The generated structures provide evidence for the discoidal, antiparallel arrangement of apoA-I in nascent HDL, and propose two preferred conformations of the flexible N-termini PMID: 28754383
    33. identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated PMID: 29287080
    34. ApoA1 is associated with neurite outgrowth after mechanical injury by mediating polymerisation of actin and restricting inflammatory responses after injury which are deleterious to healing. PMID: 27100352
    35. A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I PMID: 29030428
    36. Lower ApoA1 improves the risk prediction of new type 2 diabetes PMID: 28502492
    37. Following ETC-216 administration to normal human volunteers, an initial dose-dependent HDL-C elevation was observed. Thereafter, subjects transiently acquired a lipoprotein profile similar to that of AIM carriers, including reduced HDL-C and mild hypertriglyceridemia. PMID: 27155060
    38. The different anti-inflammatory mechanisms of the ApoA-I cysteine mutants might be associated with the regulation of ATF3 level. PMID: 28093456
    39. Anti-apoA-1 IgG are independent predictors of nonfatal incident coronary artery disease in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD. PMID: 29074586
    40. In vitro proteolysis of the apoA-I-Cy5.5 probe by a variety of proteases including serine, cysteine, and metalloproteases resulted in an up to 11-fold increase in fluorescence, allowing for quantification of apolipoprotein A-I proteolytic degradation. PMID: 28167355
    41. Using atomic force microscopy, detail the ring-shaped coarse structure, and the three detailed structures of apoA-I directly derived from spherical HDL through NP-40-induced lipid depletion. PMID: 28279834
    42. These data suggest that high doses of insulin downregulate apoA-I gene expression in HepG2 cells through redistribution of FOXO1/LXRbeta complex, FOXA2, and LXRalpha on hepatic enhancer of apoA-I gene. PMID: 27404023
    43. Our findings suggest that serum ApoA-I level should be evaluated as a predictor of survival in patients with esophageal squamous cell carcinoma PMID: 27444612
    44. Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients PMID: 28391888
    45. Serum Apo-A1 was significantly lower in term SGA newborns compared to control term newborns. PMID: 28304324
    46. This study showed that the predictive value of apolipoprotein B/A-I ratio for coronary artery calcification may differ according to kidney function. PMID: 28957410
    47. Findings suggest that the ABCG1-mediated efflux of cholesterol, but not of 7-ketocholesterol, shows specificity for structural domains of apoA-I bound to reconstituted HDL. Although the mid region alone of apoA-I associated to rHDL can promote ABCG1-mediated cholesterol efflux, deletion of carboxyl-terminal region 185-243 from full-length apoA-I diminishes ABCG1-mediated cholesterol efflux. PMID: 23826352
    48. Low APOA1 expression is associated with coronary artery disease severity. PMID: 28038449
    49. Data suggest that activation of SR-BI by APOAI down-regulates sphingosine 1-phosphate/S1PR2-mediated inflammation in vascular endothelial cells by activating the PI3K/Akt signaling pathway; oxidized-LDL does the opposite. (APOA1 = apolipoprotein A-I; SR-BI/SCARB1 = scavenger receptor class B type I; S1PR2 = sphingosine 1-phosphate receptor 2; PI3K = phosphatidylinositol 3-kinase; Akt = proto-oncogene c-akt) PMID: 28181168
    50. The minor alleles of rs662799 (APOA5) and rs5072 (APOA1) modulate TG levels in Mexican children PMID: 27171122

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    High density lipoprotein deficiency 2 (HDLD2); High density lipoprotein deficiency 1 (HDLD1); Amyloidosis 8 (AMYL8)
  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Apolipoprotein A1/A4/E family
  • 組織特異性：
    Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 600

    OMIM: 105200

    KEGG: hsa:335

    STRING: 9606.ENSP00000236850

    UniGene: Hs.93194